MilliporeSigma™ Calbiochem™ AMPK Activator III, DHPO

Description

• A cell-permeable AMPK activator (20mg/kg/d i.p
• for 21d) that has been shown to attenuate fasting blood glucose, improve glucose disposal, and correct dyslipidemia in genetic (leptin deficient, ob/ob) and dietary (high-fat-fed) mouse models of insulin resistance over controls
• IP injections for 14 days increases skeletal muscle glucose uptake by > ∽30% and ∽70% compared to vehicle-treated lean and obese mice, respectively
• Treatment with 100μM of DHPO results in a small but significant AMPK (Thr 172 ) phosphorylation, and a concentration dependent increase in glucose uptake with a 2-fold increase over controls, in cultured myotubes
• Furthermore, 20nM Compound C demonstrates a 58% and 41% inhibition of DHPO-stimulated glucose up-take at concentrations of 50μM and 100μM DHPO, respectively.